Biomarker Discovery in Alzheimer’s and Neurodegenerative Diseases using Nucleic Acid-Linked Immuno-Sandwich Assay Nicholas J. Ashton et al.
Background Recent advancements in immunological methods accurately quantify biofluid biomarkers for identifying Alzheimer’s pathology and neurodegeneration. Despite this progress, more biomarkers, ideally in blood, are needed for effective patient management and disease monitoring for Alzheimer’s disease (AD) and other neurodegenerative proteinopathies.
This Study: Using the Nucleic Acid-Linked Immuno-Sandwich Assay (NULISA™) central nervous system (CNS) panel for biomarker quantification in plasma, serum and cerebrospinal fluid (CSF) of patients with AD, mild cognitive impairment, Lewy body dementia, progranulin (GRN) mutation carriers were compared with matched controls.
Bottom Line: NULISA™ identified p-tau217 and NfL as the most significantly deregulated plasma biomarkers in the AD continuum and GRN mutation carriers, respectively. Importantly, numerous novel and significant proteomic changes were observed in each disease comparison, which included proteins involved in synaptic processing, inflammation, microglial reactivity, TDP-43 and α-synuclein pathology.
